Key Points
- CEO Paul Badawi sold 11,870 shares on Jan. 6 at an average price of $7.48 for $88,787.60 (and had sold 25,356 shares on Jan. 2), and still directly owns about 5,925,276 shares—a 0.20% reduction in his stake.
- Multiple executives disclosed clustered insider sales totaling roughly $0.48M between Jan. 2–6; each sale was a small percentage of individual holdings but the concentrated timing may exert downward pressure on the stock.
- Sight Sciences reported negative recent earnings (last quarter EPS -$0.81), has a market cap of about $395M, and carries a consensus analyst rating of Hold with an average price target near $8.30 amid mixed upgrades from firms like Piper Sandler and UBS.
Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) insider Jeremy Hayden sold 1,785 shares of the company's stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $7.48, for a total transaction of $13,351.80. Following the completion of the transaction, the insider owned 245,420 shares in the company, valued at approximately $1,835,741.60. This trade represents a 0.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Sight Sciences Price Performance
Shares of Sight Sciences stock opened at $7.47 on Wednesday. The company has a quick ratio of 8.93, a current ratio of 9.60 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $394.94 million, a price-to-earnings ratio of -8.30 and a beta of 2.42. Sight Sciences, Inc. has a twelve month low of $2.03 and a twelve month high of $9.24. The company has a 50-day simple moving average of $7.52 and a two-hundred day simple moving average of $5.13.
Sight Sciences (NASDAQ:SGHT - Get Free Report) last announced its earnings results on Wednesday, September 8th. The company reported ($0.81) EPS for the quarter. Sight Sciences had a negative return on equity of 61.59% and a negative net margin of 60.63%.The business had revenue of $12.54 million for the quarter. Analysts forecast that Sight Sciences, Inc. will post -0.99 EPS for the current year.
Analyst Upgrades and Downgrades
A number of analysts have recently weighed in on SGHT shares. UBS Group upped their target price on Sight Sciences from $7.00 to $12.00 and gave the company a "buy" rating in a research report on Tuesday, December 23rd. Lake Street Capital upped their price objective on shares of Sight Sciences from $5.00 to $7.00 and gave the stock a "buy" rating in a research report on Tuesday, October 21st. Citigroup increased their price objective on shares of Sight Sciences from $5.50 to $9.10 and gave the stock a "neutral" rating in a research note on Thursday, December 11th. Weiss Ratings restated a "sell (e+)" rating on shares of Sight Sciences in a research report on Monday, December 29th. Finally, Morgan Stanley increased their price target on shares of Sight Sciences from $6.00 to $8.00 and gave the stock an "equal weight" rating in a research report on Tuesday, December 2nd. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $8.30.
View Our Latest Research Report on SGHT
Key Sight Sciences News
Here are the key news stories impacting Sight Sciences this week:
- Positive Sentiment: Piper Sandler upgraded Sight Sciences to "Overweight" (from Neutral), which can attract institutional and retail buying and improve short-term sentiment. Read More.
- Neutral Sentiment: Insiders still retain large stakes — CEO Paul Badawi (~5.9M shares) and CTO David Badawi (~1.9M shares) — which suggests alignment with long-term value even as they trim positions; this tempers concerns that the sales signal a loss of confidence. Read More.
- Negative Sentiment: Multiple executives (CEO, CTO, CFO, EVP and other insiders) disclosed sales between Jan. 2–6 — including sizable single-day lots — totaling roughly $0.48M; although each sale is a small % of holdings, the clustered timing can create downward pressure or signal near-term liquidity needs. Read More.
Institutional Investors Weigh In On Sight Sciences
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets raised its stake in shares of Sight Sciences by 99.8% during the third quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company's stock valued at $26,000 after acquiring an additional 3,785 shares during the last quarter. CWM LLC raised its holdings in shares of Sight Sciences by 70.2% during the second quarter. CWM LLC now owns 7,607 shares of the company's stock valued at $31,000 after purchasing an additional 3,137 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of Sight Sciences by 32.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company's stock worth $48,000 after purchasing an additional 2,875 shares in the last quarter. Bank of Montreal Can acquired a new stake in Sight Sciences in the second quarter valued at approximately $49,000. Finally, R Squared Ltd acquired a new position in Sight Sciences during the third quarter worth $64,000. 55.51% of the stock is owned by institutional investors.
Sight Sciences Company Profile
(
Get Free Report)
Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company's flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye's natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.
Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
